Clinical Trial Update: Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating standard of care with or without lutetium-177 Lu-PSMA-617 in newly diagnosed metastatic hormone-sensitive prostate cancer patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: UNICANCER | Conditions: Prostate Cancer Metastatic | Phase 3 | Status: RECRUITING